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Background: The COVID-19 pandemic has caused widespread 
morbidity and mortality as well as disruption to people’s lives and 
livelihoods around the world; this has occurred as a result of both 
infection with the virus itself and the health protection measures 
taken to curb its spread. There are concerns that rates of suicide, 
suicidal behaviours and self-harm may rise during and in the 
aftermath of the pandemic. Given the likely rapidly expanding 
research evidence base on the pandemic’s impact on rates of suicide, 
suicidal behaviours and self-harm and emerging evidence about how 
best to mitigate such effects, it is important that the best available 
knowledge is made readily available to policymakers, public health 
Open Peer Review




25 Jun 2020 report report




Page 1 of 12
F1000Research 2020, 9:644 Last updated: 07 SEP 2020
specialists and clinicians as soon as is possible. To facilitate this, we 
plan to undertake a living systematic review focusing on suicide 
prevention in relation to COVID-19. 
Method: Regular automated searches will feed into a web-based 
screening system which will also host the data extraction form for 
included articles. Our eligibility criteria are wide and include aspects of 
incidence and prevalence of suicidal behaviour, effects of exposures 
and effects of interventions in relation to the COVID-19 pandemic, 
with minimal restrictions on the types of study design to be included. 
The outcomes assessed will be death by suicide; self-harm or 
attempted suicide (including hospital attendance and/or admission for 
these reasons); and suicidal thoughts/ideation. There will be no 
restriction on study type, except for single case reports. There will be 
no restriction on language of publication. The review will be updated 
at three-monthly intervals if a sufficient volume of new evidence 
justifies doing so. 
Conclusions: Our living review will provide a regular synthesis of the 
most up-to-date research evidence to guide public health and clinical 
policy to mitigate the impact of COVID-19 on suicide. 
Protocol registration: PROSPERO CRD42020183326 01/05/2020
Keywords 
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harm, Suicidal thoughts
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Introduction
The COVID-19 pandemic is causing widespread disruption 
and loss of life globally. By mid-May 2020 over 4.4 million 
people had been infected and 300,000 had died [https://www.
worldometers.info/coronavirus/]. There are concerns about the 
impact of the pandemic on population mental health (Holmes 
et al., 2020). These stem from the impact of the virus itself on 
the people infected, as well as front line workers caring for 
them (Kisely et al., 2020), and from the public health measures 
to minimise spread of the virus – in particular physical distanc-
ing, leading to social isolation, disruption of work, businesses 
and education. Physical distancing measures have resulted in 
substantial rises in unemployment, falls in GDP and concerns 
that many nations will enter a period of deep economic recession.
There are concerns that suicide and self-harm rates may rise 
during and in the aftermath of the pandemic (Gunnell et al., 
2020; Reger et al., 2020). Time-series modelling indicated that 
the 1918–20 Spanish Flu Pandemic, which caused well over 
20 million deaths worldwide, led to a modest rise in the national 
suicide rate in the USA (Johnson & Mueller, 2002; Wasserman, 
1992). Likewise, there is evidence that suicide rates increased 
briefly amongst people aged over 65 in Hong Kong dur-
ing the 2003 SARS epidemic, predominantly amongst those 
with more severe physical illness and physical dependency 
(Cheung et al., 2008).
The current context is, however, very different from previ-
ous epidemics and pandemics. The 2003 SARS epidemic was 
restricted to relatively few countries. Furthermore, in the time 
since the 1918–20 influenza pandemic, global and national 
health systems have improved, international travel and the 
speed of communication of information (and disinformation) 
have increased, antibiotics are available to treat secondary infec-
tion, and national economies have become more inter-dependent. 
The availability of the internet and technology for communica-
tion has made it easier for people to communicate and engage 
in home working and home schooling. However, there are huge 
inequalities in relation to access to technology and ability to stay 
safe and continue to work, within and between countries. Pub-
lic health policies and responses, and the degree of access to 
technology to facilitate online clinical assessments and treatments 
differ greatly between countries.
Key concerns in relation to suicide prevention include: uncer-
tainty regarding how best to assess and support people with 
suicidal thoughts and behaviours, whilst maintaining physi-
cal distancing; people who have attempted suicide may not 
attend hospitals because they are worried about contracting 
COVID-19 or being a burden on the healthcare system at this 
time; the uncertain impact on mental health and risk of sui-
cide in the general population of physical distancing; an eco-
nomic recession may adversely impact on suicide rates (Chang 
et al., 2013; Stuckler et al., 2009). There may be an increase 
in prevalence of suicide risk factors such as mental illness, 
domestic violence, alcohol misuse and bereavement (Turecki 
et al., 2019); the insensitive or irresponsible media reporting 
of suicide deaths associated with COVID-19 may be harmful; 
and in some countries access to highly lethal suicide methods 
such as firearms and pesticides may rise (Gunnell et al., 2020).
In the context of the COVID-19 pandemic there is likely to 
be a rapidly expanding research evidence base on its impact 
on suicide rates, and how best to mitigate such effects. It is 
therefore important that the best available knowledge is made 
rapidly available to policymakers, public health specialists 
and clinicians. To facilitate this, we plan to conduct a living sys-
tematic review focusing on suicide prevention in relation to 
COVID-19. Living systematic reviews are high-quality, up-to-
date online summaries of research that are regularly updated, 
using efficient, often semi-automated, systems of production 
(Elliott et al., 2014).
Aim
The overarching aim of the review is to identify and appraise 
any newly published evidence from around the world that 
assesses the impact of the COVID-19 pandemic on suicide 
deaths, suicidal behaviours, self-harm and suicidal thoughts, or 
that assesses the effectiveness of strategies to reduce the risk 
of suicide deaths, suicidal behaviours, self-harm and suicidal 
thoughts, resulting from the COVID-19 pandemic.
Methods
We will undertake a living systematic review (Figure 1) following 
published guidance for such reviews and for how expediated 
‘living’ recommendations should be formed where relevant 
(Akl et al., 2017; Elliott et al., 2017). The review was pro-
spectively registered (PROSPERO ID CRD42020183326; 
registered on 1 May 2020). This protocol is reported in line 
with the Preferred Reporting Items for Systematic Review and 
Meta-Analysis Protocols guideline (Moher et al., 2015).
Eligibility criteria
Study participants may be adults or children of any ethnicities 
living in any country. Outcomes of interest are: 
1.      Deaths by suicide
2.      Self-harm (intentional self-injury or self-poisoning 
regardless of motivation and intent) or attempted sui-
cide (including hospital attendance and/or admission 
for these reasons)
3.      Suicidal thoughts/ideation
Studies must address one of the following research questions: 
(i) What is the prevalence/incidence?
•      Prevalence/incidence of each outcome during pandemic 
(including modelling studies to predict incidence / 
prevalence)
(ii) What is the comparative prevalence/incidence?
•      Prevalence/incidence of each outcome during pandemic 
vs not during pandemic
(iii) What are the effects of interventions?
•      Effects of public health measures to combat COVID-19 
(including physical distancing, school closures, 
interventions to address loss of income, interventions 
to tackle domestic violence) on each outcome
Page 4 of 12
F1000Research 2020, 9:644 Last updated: 07 SEP 2020
•      Effects of changed and new approaches to clinical 
management of (perceived) elevated risk of self-harm or 
suicide risk on each outcome (any type of intervention 
is relevant)
(iv) What are the effects of other exposures?
•      Impact of media portrayal of each outcome and mis-
information attributed to the pandemic on each 
outcome
•      Impact of bereavement from COVID-19 on each outcome
•      Impact of any COVID-19 related behaviour changes 
(domestic violence, alcohol, cyberbullying) on each 
outcome
•      Impact of COVID-19-related workload on crisis lines on 
each outcome
•      Impact of infection with COVID-19 (self or family 
member) on each outcome
•      Impact of increased availability of analgesics, firearms 
and pesticides on each outcome (method-specific and 
overall suicide rates)
•      Impact of COVID-19 related socio-economic exposures 
(recession/depression: unemployment, debt, deprivation 
at the person-, family- or small-area level) on each 
outcome
•      Impact on health and social care professionals: the stigma 
of working with COVID-19 patients or the (perceived) 
risk of infection/being a ‘carrier’, as well as work- 
related stress on each outcome
•      Impact of changes in/reduced intensity of treatment for 
patients with mental health conditions, in particular 
those with severe psychiatric disorders.
•      Impact of any other relevant exposure on our outcomes 
of interest.
Qualitative research. We will include any qualitative research 
addressing perceptions or experiences around each outcome in 
relation to the COVID-19 pandemic (e.g. stigma of infection, 
isolation measures, complicated bereavement, media reporting, 
experience of remote methods of self-harm / suicide risk assess-
ment or provision of treatment; experience of seeking help for 
Figure 1. Workflow for updating the living review. The process will be supported using automation technology and in three-month intervals 
reviewers will decide on extracting new data and updating the review.
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individuals in suicidal crisis); narratives provided for precipitating 
factors for each outcome.
No restrictions will be placed on the types of study design 
eligible for inclusion, with the exception of single case reports. 
Pre-prints will be assessed at the time of publication. There 
will be no restriction on language of publication. We will 
draw on a combination of internet-based translation systems 
and network of colleagues to translate evidence in a language 
other than English.
Identification of eligible studies
We will search the following electronic databases: PubMed; 
Scopus; medRxiv, bioRxiv; the COVID-19 Open Research 
Dataset (CORD-19) by Semantic Scholar and the Allen Institute 
for AI, includes relevant records from Microsoft Academic, Else-
vier, arXiv and PMC); and the WHO COVID-19 database. A 
sample search strategy (for PubMed) appears in Box 1. We have 
developed a workflow that automates daily searches of these 
databases, and the code supporting this process can be found at 
https://github.com/mcguinlu/COVID_suicide_living (McGuinness 
& Schmidt, 2020)). Searches are conducted daily via PubMed 
and Scopus application program interface and the bioRxiv and 
medRxiv RSS feeds. Conversion scripts for the daily updated 
WHO and the weekly updated CORD-19 corpus are used to collect 
information from the remaining sources. The software includes a 
systematic search function based on regular expressions to 
search results retrieved from the WHO, CORD-19 and preprint 
repositories (search strategy available as extended data (John 
et al., 2020)). We will investigate the use of other databases to 
capture papers made available prior to peer review and assess 
eligibility and review internally.
Box 1. Search terms for PubMed
((selfharm*[TIAB] OR self-harm*[TIAB] OR selfinjur*[TIAB] OR 
self-injur*[TIAB] OR selfmutilat*[TIAB] OR self-mutilat*[TIAB] 
OR suicid*[TIAB] OR parasuicid*[TIAB) OR (suicide[TIAB] 
OR suicidal ideation[TIAB] OR attempted suicide[TIAB]) 
OR (drug overdose[TIAB] OR self?poisoning[TIAB]) OR 
(self-injurious behavio?r[TIAB] OR self?mutilation[TIAB] 
OR automutilation[TIAB] OR suicidal behavio?r[TIAB] OR 
self?destructive behavio?r[TIAB] OR self?immolation[TIAB])) 
OR (cutt*[TIAB] OR head?bang[TIAB] OR overdose[TIAB] OR 
self?immolat*[TIAB] OR self?inflict*[TIAB]))) AND ((coronavirus 
disease?19[TIAB] OR sars?cov?2[TIAB] OR mers?cov[TIAB]) 
OR (19?ncov[TIAB] OR 2019?ncov[TIAB] OR n?cov[TIAB]) 
OR (“severe acute respiratory syndrome coronavirus 2” 
[Supplementary Concept] OR “COVID-19” [Supplementary 
Concept] OR COVID-19 [tw] OR coronavirus [tw] OR nCoV[TIAB] 
OR HCoV[TIAB] OR ((virus*[Title] OR coronavirus[Title] 
OR nCoV[Title] OR infectious[Title] OR HCoV[Title] OR 
novel[Title])AND (Wuhan[Title] OR China[Title] OR Chinese[Title] 
OR 2019[Title] OR 19[Title] OR COVID*[Title] OR  
SARS-Cov-2[Title] OR NCP*[Title]) OR “Coronavirus”[MeSH]))))
A two-stage screening process will be undertaken to iden-
tify studies meeting the eligibility criteria. First, two authors 
(either CO or EE) will assess citations from the searches and 
identify potentially relevant titles and abstracts. Second, either 
DG, AJ or RW will assess the full texts of potentially eligible 
studies to identify studies to be included in the review. This proc-
ess was managed via a custom-built online platform (Shiny web 
app, supported by a MongoDB database). The platform also 
allows for data extraction via a built-in form (extended data 
(John et al., 2020)). At the time of writing we are processing new 
records virtually every working day. Regularity of this task may 
reduce over time though it will be done at least monthly. We 
have the resources to display the current state of the review and 
screening process publicly on a regular basis.
Data collection and assessment of risk of bias
One author (DG, AJ or RW) will extract data from each included 
study using a piloted data extraction form (extended data (John 
et al., 2020)), and the extracted data will be checked by one 
other author. Disagreements will be resolved in the first instance 
through discussion, and where this fails, by referral to a third 
reviewer (KH or NK). Irrespective of study design, data source 
and outcome measure examined, the following basic data 
will be extracted: citation; study aims and objectives; country/
setting; characteristics of participants; methods; outcome meas-
ures (related to suicidal behaviour and COVID-19); key findings; 
strengths and limitations; reviewer’s notes. For articles where 
causal inferences are made i.e. randomized or non-randomized 
studies examining the effects of interventions or aetiological 
epidemiological studies of the effects of exposures, we will 
use a suitable version of the ROBINS-I or ROBINS-E tool to 
assess risk of bias as appropriate based on the research question 
and study design (Morgan et al., 2017; Sterne et al., 
2016).
Data synthesis
We will synthesise studies according to themes based on 
research questions, using tables and narrative. Results will be 
synthesised separately for studies in the general population, in 
health and social care staff and other at-risk occupations, and in 
vulnerable populations (e.g. people of older age or those 
with underlying conditions that predispose them to becoming 
severely ill or dying after contracting Covid-19). Where multiple 
studies address the same research questions, we will assess 
whether meta-analysis is appropriate and conduct it where 
suitable following standard guidance available in the Cochrane 
Handbook (Deeks et al., 2019).
Living mode of the review, and transition to a static state
We plan to maintain the review in living mode for at least 
12 months, from publication of the protocol. We will under-
take monthly screening and consider full updates considered at 
least every 3 months, if sufficient relevant evidence is published, 
although these are likely to happen monthly in the first instance. 
We will extend the living mode at 6-monthly intervals if evi-
dence is still being published regularly. We anticipate an end 
to the living phase of the review at most 24 months after initia-
tion, at which point we plan to publish the cumulated evidence 
in the form of a standard systematic review. Our decision to 
update the review will depend on the likely impact of the new 
evidence on the conclusions of the review. Impactful evidence 
may be (i) evidence that affects policy and/ or (ii) substantial, 
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high-quality research studies (e.g. a randomised trial or 
population-based observational cohort study).
When a decision is made to move to from a living review to 
a static publication, two reviewers will independently assess 
10% of all citations screened to determine whether any records 
were likely to have been missed, with further independent 
screening in the case of concerns. In addition, all extracted data 
will be checked against each relevant paper by an additional 
reviewer.
Justification for a living method
In the context of the COVID-19 pandemic there is a high 
level of uncertainty relating to its impact on suicide rates 
and how best to mitigate such effects and there is likely to 
be a rapidly emerging research evidence base to address this 
(Gunnell et al., 2020; Holmes et al., 2020; Reger et al., 2020). 
It is therefore important that the best available knowledge is 
made rapidly available to policymakers, public health specialists 
and clinicians to inform their practice.
Dissemination of information
This living review, along with further updates, will be published 
via F1000Research. This review was registered on PROSPERO, 
with ID CRD42020183326. All further data are publicly avail-
able via our Harvard Dataverse repository including all results 
of the continuous evidence surveillance and screening. Findings 
from the review will be widely disseminated through 
conference presentations, policy briefings, peer-reviewed 
publications, a project website, and traditional and social media 
outlets. Many of the co-authors are members of the International 
Covid-19 suicide prevention research collaboration (IPCSPRC), 
we will also use this network and its partnership with the Inter-
national Association for Suicide Prevention to disseminate 
findings.
Study status
We are currently searching and screening on a daily basis.
Data availability
Underlying data
No data are associated with this article.
Extended data
Harvard Dataverse: Underlying data for: The impact of the 
Covid-19 pandemic on suicidal behaviour: a living system-
atic review protocol. https://doi.org/10.7910/DVN/9JYHLS  
(John et al., 2020)
This project contains the following extended data:
•     Search.docx (additional information about the searches, 
including full search strategies)
•     data_extraction_form.docx (Data extraction sheet/study 
report)
•      lsr_fig1.png (Figure 1 from protocol)
•      PROSPERO_registration.pdf (Prospero registration)
Reporting guidelines
Harvard Dataverse: PRISMA-P checklist for ‘The impact of 
the COVID-19 pandemic on self-harm and suicidal behaviour: 
protocol for a living systematic review’ https://doi.org/10.7910/
DVN/9JYHLS (John et al., 2020) 
Software availability
The development version of the software for automated 
searching is available from Github: https://github.com/mcguinlu/
COVID_suicide_living.
Archived source code at time of publication: http://doi.org/ 
10.5281/zenodo.3871366 (McGuinness & Schmidt, 2020)
License: MIT
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This paper presents a protocol for a living systematic review on the impact of COVID-19 pandemic 
on self-harm and suicidal behaviour. This is an important and timely review. 
 
Suicidal and self-harm behaviours have increased during previous epidemics and pandemics and 
there are good theoretical reasons to believe that a similar patter will occur during the COVID-19 
pandemic. The review aims to rapidly provide real-time evidence of the impact of COVID-19 
pandemic on suicide deaths, suicidal behaviours, self-harm, and suicidal thoughts, and to assess 
the effectiveness of strategies that aim to reduce these. 
 
The review is a mixed-method in design and will include both quantitative and qualitative (except 
single case studies in either method). The protocol is well described and presented in line with 
PRISMA guidelines. 
 
PsychInfo is not included as one of the listed search engines, which appears to be an omission. 
The link to medRxiv is broken. 
 
Factors for the authors to consider are as follows. How the authors will assess bias in quantitative 
research is clearly described. However, it is unclear how the authors will review the quality of 
qualitative studies. It is also unclear how the qualitative data will be synthesised with the 
quantitative data and inform the review of effectiveness study. The living systematic-review design 
lends itself to a greater integration of both quantitative and qualitative data as they are published. 
 
The transition of the review to a static state and the dissemination strategy is well described.
 
Is the rationale for, and objectives of, the study clearly described?
Yes
Is the study design appropriate for the research question?
 
Page 9 of 12
F1000Research 2020, 9:644 Last updated: 07 SEP 2020
Yes
Are sufficient details of the methods provided to allow replication by others?
Yes
Are the datasets clearly presented in a useable and accessible format?
Not applicable
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undertaking 3 COVID-19 related studies, including two in mental health contexts.
I confirm that I have read this submission and believe that I have an appropriate level of 
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Tari Turner  
Monash University, Melbourne, Australia 
This is a clear and well written protocol for a living systematic review of evidence on the impact of 
the COVID-19 pandemic on self-harm and suicidal behaviour. This is an important topic, a living 
systematic review approach is clearly useful for this topic at this time, and the methods described 
are also appropriate. 
 
I note that the review questions are complex and this will both make the review more useful, but 
also more challenging to do and to describe. 
 
Is there any plan to review the search strategy to ensure the terms used remain appropriate? Will 
non-English studies be included?  Have searches of trials registers been conducted to determine 
the likely workload over coming months? 
 
I would encourage the authors to provide more clarity on the approach and criteria they will use 
to make decisions about:
changing the frequency of screening 
 
○
whether there is “sufficient relevant evidence” to justify an update.○
Ideally enough detail should be provided on these to allow another team to make the same 
decisions, using the same criteria; and I don’t think this is true of the descriptions as they currently 
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stand. 
 
For example, some other living review teams have committed to updating their reviews when new 
evidence is likely to have a clinically meaningful impact on the size of the effect, or change the 
direction or degree of certainty (GRADE) of the effect for key outcomes. I recognise that the 
complexity of the review questions and types of evidence being included in this review may make 
this challenging, but additional explanation would be helpful, and avoid potential future 
perceptions of bias based on these decisions. (These decisions may also require that some 
elements of data extraction and ROB assessment are taken before a decision to update is 
undertaken, and this should be considered for workflows.) 
 
Also there is some confusion between the Figure and the text, with the figure appearing to 
suggest that update decisions are made 3 monthly, while the text suggests these decisions may 
initially be more frequent (monthly?); and the figure suggesting that screening is conducted daily 
(presumably 5/7?) but there is some ambiguity about commitment to this in the text. 
 
I recommend review of the article by a person with clinical expertise in the area, as I do not have 
these skills, and I look forward to reading the review.
 
Is the rationale for, and objectives of, the study clearly described?
Yes
Is the study design appropriate for the research question?
Yes
Are sufficient details of the methods provided to allow replication by others?
Partly
Are the datasets clearly presented in a useable and accessible format?
Not applicable
Competing Interests: No competing interests were disclosed.
Reviewer Expertise: Living evidence synthesis methods.
I confirm that I have read this submission and believe that I have an appropriate level of 
expertise to confirm that it is of an acceptable scientific standard, however I have 
significant reservations, as outlined above.
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